Case Study:

Showcasing the Totality of Evidence for a CDK4/6 Inhibitor in Breast Cancer

Introduction

Chris from Quill Science partnered with a U.S.-based mid-sized medical marketing agency to develop high-impact scientific content for a pharmaceutical client promoting a CDK4/6 inhibitor used in advanced and early breast cancer. The client needed to summarize the product’s full clinical value across diverse treatment settings, from first-line metastatic disease to adjuvant therapy.

With expanding indications and a complex treatment landscape, the agency turned to Quill Science to help synthesize the data into a coherent story. The result was a compelling suite of deliverables that unified clinical trial evidence, communicated differentiation, and helped the agency exceed client expectations—without burdening their internal teams.

Challenge

The agency was tasked with delivering a “Totality of Evidence” deck and manuscript that translated data from seven clinical trials into a persuasive, scientifically rigorous narrative. The scope spanned multiple treatment lines—each with distinct endpoints, dosing strategies, and outcomes.

The agency needed a strategic medical lead who could:

• Bring scientific rigor to oncology data interpretation

• Integrate messaging across clinical stages

• Adapt to stakeholder input

• Deliver strategy and execution fast

Solution

Strategic Collaboration & Execution

Chris was brought in to guide strategic messaging and lead content development. Over a 5-month engagement, Chris served as an embedded medical strategist and writer, offering a seamless extension to the agency’s internal team.

What We Did

• Literature Synthesis: Reviewed and integrated findings from seven clinical trials, real-world data, and published literature.

• Data Structuring: Organized efficacy and safety data across lines of therapy—highlighting value in early and late-stage disease.

• Messaging Alignment: Emphasized differentiators like overall survival, tolerability, and monotherapy opportunity using our CASE framework.

• Content Development: Drafted a comprehensive slide deck and a peer-reviewed manuscript aligned with the client’s evolving strategic priorities.

Results

Key Deliverables

• A polished slide deck that clearly articulated the clinical value of the CDK4/6 inhibitor across treatment lines.

• A near-submission-ready draft of a review article for a peer-reviewed journal.

• Strategic narrative guidance across other client deliverables.

Agency and Client Wins

• The agency expanded its credibility with the client by delivering publication-quality materials under pressure.

• Chris’s reliability, knowledge in oncology, and ability to reshape content to match shifting feedback cycles helped extend the collaboration beyond the initial scope.

• The project led to additional discussions around future workstreams, reinforcing Chris’ role as a trusted partner.

Conclusion

This project showcases how Quill Science enables agencies to scale their scientific output and deliver strategic value—without stretching internal teams. Whether your challenge is lack of time, limited oncology expertise, or fragmented messaging, Quill Science brings the clarity, rigor, and partnership needed to elevate your client work.